Concepedia

Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients

Valentín García‐Gutiérrez, Dragana Milojković, Juan Carlos Hernández‐Boluda, Simone Claudiani, María Luisa Martín Mateos, Luis Felipe Casado-Montero, G. González, Antonio Jiménez‐Velasco, Concepción Boqué, Alejandra Martínez‐Trillos,

Annals of Hematology · 2018 · 26 citations · 15 references

DOI

Concepts

References

15

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil et al. · New England Journal of Medicine · 2010 · 1.7K citations · Full text

, , +10

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

Jörge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian et al. · Journal of Clinical Oncology · 2016 · 946 citations · Full text

, , +12

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes et al. · Leukemia · 2016 · 850 citations · Full text

, , +11

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger et al. · Journal of Clinical Oncology · 2017 · 493 citations · Full text

, , +12

<i>In vitro</i> and <i>In vivo</i> Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells

Miriam Puttini, Addolorata Maria Luce Coluccia, Frank Boschelli et al. · Cancer Research · 2006 · 371 citations

, , +11